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INTERACTIONS between antibiotics and
negatively charged substances have
already been described (Jacobs et al.,
1973; Jacques, 1979). In particular adria-
mycin, an anthracycline antibiotic widely
used as an anticancer agent, has been
shown to form ionic associations with
negatively charged phospholipids, and to
give rise to complexes with sulphated
mucopolysaccharides such as heparin and
chondroitinsulphate (Menozzi & Arca-
mone, 1978). When adriamycin and
heparin are administered simultaneously,
as occurs in some cancer patients (Hilgard
& Thornes, 1976), a temporary reduction
of the anticoagulant activity of lieparin
may ensue (Cofrancesco et al., 1980).
Daunomycin (DNM), an aminoglyco-
sidic antibiotic the structure of which is
very similar to that of adriamycin, is
widely used in the treatment of acute
leukaemias (Jacquillat et al., 1979) and is
therefore very often associated with
heparin in order to prevent disseminated
intravascular coagulation and subsequent
fatal haemorrhage (Nomura et al., 1974;
Drapkin et al., 1978).
In this paper, we evaluate the possible
interactions between DNM and heparin in
acute leukaemia patients treated with a
standard clinical protocol.
Eighteen cycles of DNM treatment (in
15 patients) were studied; in each second
cycle DNM was associated with heparin
treatment. Complete evaluation of DNM
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disappearance curves was only possible in
15 cycles (9 cycles in 9 patients receiving
DNM, Group A, and 6 cycles in 5 patients
receiving DNM +heparin, Group B) in
view of difficulties in collecting serial
blood samples in 3 cycles (all in Group B).
Table I reports the clinical diagnosis,
peripheral blood and marrow findings, and
an indication of liver function for all of
the patients studied. None of them had
signs of haemolysis or impaired renal
function. The diagnosis of acute leuk-
aemia was established on the basis of
morphological criteria in cells from peri-
pheral blood and marrow (Bennett et al.,
1976).
Patients in Group A received DNM
2 mg/kg i.v. on Day I and Ara-C 2 mg/kg
i.v. with 6-thioguanine 2 mg/kg per os
daily on Days 2-6. Patients in Group B
received the same treatment as GCroup A
patients, but were also given a heparin
infusion (20,000 i.u. over 12 h) on Day 1,
starting when DNM was given. Two
patients (Nos 4 and 6) were studied twice,
both when they received DNM alone and
when they received the association of
DNM and heparin. One patient (No. 10)
was studied during 2 consecutive cycles of
DNM associated with heparin. The heparin
used was Liquemin, Roche, Milano, Italy.
Twelve blood samples were collected
from each patient (from the antecubital
vein contralateral to that where DNM was
given) at intervals from 5 min to 24 h783 TIEPARIN AND DAUNOMYCIN IN ACUTE LEUKAEMIA
TABLE I. Clinical data on the patients studied
Patient
No. Sex Age
Group A
1 F 23
2 F 39
3 F 63
4A Al 36
5 MI 43
6A F 22
7 F 37
8 F 54
9 MI 68
Group B
4B MI 36
6B F 22
10 F 55
11 F 70
12 1\I 50
Body
wt
(kg) Diagnosis
75
50
60
80
80
63
60
75
87
80
63
50
50
65
75
MI3
A.14
I12
M2
\1
Lo
L2
m1
tIoI
Lo
Cycle
DNMAl\ of
(mg tot) therapy
150
100
120
160
160
126
120
150
174
160
126
100
100
130
150
4
1
2
1
1
1)
I
I
2
1
1
Marrow
blasts r-
(0/0) v
<1
<1
20
<1
90 1
90 3
90
90
90
90
90 1
40
50
90
90 2(
Blood
ATBC/)ul Blasts (%) Liver function
4,200
9,100
3,800
5,300
50,000
31,900
6,000
3,000
26,200
3,700
16,200
3,500
3.900
6,500
00,000
0
0
9
0
98
77
1
9
85
7
50
7
0
17
100
Normal
Normal
Normal
Normal
Impaired*
Normal
Tmpairedt
Normal
Impaired:
Normal
Normal
Normal
Normal
Normal
Normal
M1: myeloblastic leukaemia withlout maturation.
M2: myeloblastic leukaemia with maturation.
M3: hypergranular promyelocytic leukacmia.
M4: myelomonocytic leukacmia.
L2: lymphoblastic leukaemia with heterogeneous cells.
* Abnormal: alkaline phosphlatase and y-glutamil transferase (y-GT).
t Abnormal: total bilirubin; SGOT-SGPT; y-GT, plasma protein pattern.
I Abnormal: alkaline phosphatase, SGOT-SGPT, y-GT, plasma protein patterin.
after DNM administration. In Group B
patients, blood was collected before the
start of heparin treatment too, and at
various intervals during the joint drug
treatment for measurement of thrombin
time.
Venous blood was drawn into test tubes
containing 1 part of 0126M trisodium
citrate to 9 parts of blood. The samples
were immediately centrifuged for 20 min
at 4000 rev/min and supernatant cell-free
plasma was stored at - 20°C until use.
Total plasma DNM-associated fluores-
cence was measured according to Finkel
et al. (1969), thrombin time was measured
according to Vermylen & Verstraete
(1960).
The time course of DNM plasma con-
centrations for each patient was tested for
linear regression before being fitted to the
triexponential equation: ln C=ln (A e-at
+B e-fIt+C e-vt)
The correlation coefficients were statis-
tically significant, thus confirming a good
fit to the model adopted.
Pharmacokinetic parameters considered
were: apparent halflives (t1/2); areaunder
the curve (AUCS), theoretical area under
the curve (AUCT); the apparent volume of
distribution (Vd) and plasma clearance
(Clp) (Wagner, 1971).
Fourteen of the 15 cycles of DNM treat-
ment monitored fitted a 3 compartment
open-model pharmacokinetic analysis.
Patient No. 12 with L2 leukaemia was ex-
cluded, as his DNM plasma levels were at
a plateau and more appropriately fitted a
one compartment model. Fig. 1 shows
plots ofthe theoretical plasma DNM decay
for Groups A and B. In Group A, the
curves of patients 8 and 9, who had L2
leukaemia, are marked with a broken line
in the graph, and have been considered
separately in further evaluation.
The kinetic profile of the 2 groups of
curves was superimposable, the results
being somewhat more variable in Group A
than in Group B, as was indicated by the
generally higher standard deviation (s.d.)
and the wider range of kinetic parameters
of this group (Table II). Plasma dis-
appearance of DNM in Patients 4 and 6
followed similar kinetics both in the pre-
sence and absence of heparin.E. PIAZZA ET AL.
TABLE II.-Pharmacokinetic parameters of DNM disappearance from plasma of acute
leukaemia patients
Cip
Vd (1) (ml/min)
125
541
67
131
135
112
303
132 + 81
201
201
580
62
158
240+ 198
0 74
0-91
0-17
0-48
2-17
0-42
0-2
0-74 + 0-86
0-46
044
0-65
0-22
0-32
0-42 + 0-16
GROUP A COMM1)
U.01.
o
. -
FiG. Theoretical DNM plasma decay curves
in the two groups ofpatients.
Among Group A patients, Nos 1 and 5
scored the lowest AUC values (both AUCS
and AUCT) and the shortest y half-life;
their a and : half lives were in the same
range as the other patients. These 2
patients eliminated the drug very fast, as
at 12 h after treatment their plasma DNM
levels were at the sensitivity limit of the
analytical method. One of them, No. 5,
had slight impairment of liver function
(Table I). No. 7 too had liver impairment
before treatment; she had the highest
absolute y half-life, but her other phar-
macokinetic parameters were in the nor-
mal range, as confirmed by the plasma
decay curve (Figure and Table II).
In Group B all the patients had normal
liver function, and all but one were at the
first cycle of therapy. In Patient No. 10,
the pharmacokinetic parameters differed
somewhat in the second cycle from the
first, but the differences (shorter : half-
life, higher AUC) were approximately
within one s.d. of the mean.
Table III gives the results in 3 patients
with L2. In the 2 whose DNM decay fitted
a 3-exponential pattern, the first phase of
distribution was normal, but elimination
was much slower than the average Group
A value. The parameters measured in
Patient 12 failed to show any disappear-
ance of the drug during the test period,
further supporting the suggestion that, in
this type of leukaemia, DNM disappears
particularly slowly.
AUCs
(Kg/ml
-,af (min) T.:0 (min) T,y (min) x min)
Patient
No. T
Group A
1
2
3
4A
5
6A
7
Mean + s.d.
Group B
4B
6B
10 (1st cycle)
(2nd cycle)
11
Mean + s.d.
2-7
3-6
5-7
2-6
2-7
2-9
4 0
3-4+ 1-1
4-7
3-1
6-2
5-7
5-4
5 0 + 1-2
62
29
17
27
41
20
25
31-6+ 15-4
20
22
36
12
18
22-0 + 8-8
1019
408
1307
1066
485
976
1732
999 + 457
1386
1358
1283
1307
2165
1500 + 374
AUCT
(Kg/ml
x min)
206
105
535
335
72
304
483
291 + 177
341
286
233
336
405
320 + 64
130-5
72
339
195
47
199
218
172 + 98
176
149
129
179
154
157 + 21
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TABLE III.-Pharmacokinetic parameters of DNATM disappearance from plasma in L2
patients
AUC.s
( tg/ml
Tc. (mmii) Tfl (mmii) T7y (min) x min)
5 20 4950
2-4 50 2165
1(05*
270
172
210
AUCT
( ig/ml
x min)
1455
449
Clt)
Vd (1) (ml/min)
6 0-10
81 0:37
335 814 0:33
* I-compaltment moclel.
In Group B patients, an optimal degree
of anticoagulation was achieved immedi-
ately (5 min) and at various intervals
(10, 15, 30 and 60 min) after administra-
tion of DNM (data not shown).
This study shows that the concomitant
administration of heparin does not modify
DNM disappearance curves in a group of
acute leukaemia patients. Since the re-
sults were obtained with a method which
measures total fluorescence linked to
DNM and to its metabolites, we cannot
rule out the possibility that the relative
proportions of the intact drug and its
metabolites would be changed in the
presence of heparin. The DNM plasma
decay curves could be well fitted to a
triphasic pattern, as Huffman et al. (1972)
reported for total DNM fluorescence in a
population of acute leukaemia patients.
The DNM plasma levels we found were
lower than those obtained bv Huffman et
al. (1972) after administration of double
our dose, but were similar to those re-
ported by Alberts et al. (1971) in patients
with solid tumours treated with the same
DNM dose. Although the pharmacokinetic
parameters of DNM decay in the 2 groups
did not differ significantly, the values
obtained in association with heparin pre-
sented less variability.
This might reflect a simpler pattern of
metabolism and/or distribution of DNM
in heparinized blood. The greater fluidity
of the anticoagulated blood could reduce
vascular stress, favouring systemic drug
circulation and, probably, its uptake by
tissues and organs too. It should also be
noted that all the patients who received
heparin had normal liver function, whereas
3 patients in Group A had one or more
signs of liver impairment. However, in
Group A patients, signs of liver impair-
ment were not necessarily accompanied
by any gross abnormality of pharmaco-
kinetic parameters. All but one of the
Group B patients, but onlv 2 of the
patients in Group A were at the first cycle;
this could be another factor favouring
homogeneity of the pharmacokinetic data
in Group B.
Three of the patients under study had
L2 leukaemia, 2 in Group A and the third
in Group B. All 3 appeared to eliminate
DNM at a much slower rate than the
others with M leukaemia. The 2 in Group
A scored the highest y half-lives and the
one in Group B had constant plasma levels
of DNM up to 24 h after administration.
More detailed study is obviously required
to establish whether such a peculiarity of
the 3 patients is linked to the cell type
characterizing their leucocyte population
or to some other cause.
The lack of any substantial interference
by heparin on the plasma disappearance
of DNM suggests that no clinically signifi-
cant interaction occurs between the two
drugs at the dosages used. This is further
confirmed by the observation that heparin-
induced anticoagulation was not modified
by the presence of DNM. On the other
hand, the formation of a chemical com-
plex between DNM and heparin in certain
experimental conditions cannot be ex-
cluded on the basis of our data.
Formation of such a complex has been
reported between adriamycin and heparin,
Patient
N.o.
Group A
8
9
Group B
12
78.786 E. PIAZZA ET AL.
and heparin anticoagulation was transi-
ently recluced by adriamycin both in
humans (Cofrancesco et al., 1980) and in
mice (Poggi et al., submitted). However,
in mice, even this interaction did not
cause marked interference with either the
plasma disappearance and tissue distribu-
tion or the antitumoral activity of the
drug.
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